BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16390276)

  • 1. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression.
    Lamers CH; Gratama JW; Pouw NM; Langeveld SC; Krimpen BA; Kraan J; Stoter G; Debets R
    Hum Gene Ther; 2005 Dec; 16(12):1452-62. PubMed ID: 16390276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
    Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
    Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.
    Lamers CH; Willemsen RA; van Elzakker P; van Krimpen BA; Gratama JW; Debets R
    Cancer Gene Ther; 2006 May; 13(5):503-9. PubMed ID: 16282986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
    Lamers CH; Willemsen RA; Luider BA; Debets R; Bolhuis RL
    Cancer Gene Ther; 2002 Jul; 9(7):613-23. PubMed ID: 12082462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
    Lamers CH; Langeveld SC; Groot-van Ruijven CM; Debets R; Sleijfer S; Gratama JW
    Cancer Immunol Immunother; 2007 Dec; 56(12):1875-83. PubMed ID: 17479266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
    Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
    Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules.
    Weijtens ME; Willemsen RA; van Krimpen BA; Bolhuis RL
    Int J Cancer; 1998 Jul; 77(2):181-7. PubMed ID: 9650549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
    Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
    Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
    Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9.
    Mukouyama H; Janzen NK; Hernandez JM; Lam JS; Caliliw R; Wang AY; Figlin RA; Belldegrun AS; Zeng G
    Clin Cancer Res; 2004 Feb; 10(4):1421-9. PubMed ID: 14977845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells.
    Li G; Passebosc-Faure K; Lambert C; Gentil-Perret A; Blanc F; Oosterwijk E; Mosnier JF; Genin C; Tostain J
    Clin Cancer Res; 2001 Jan; 7(1):89-92. PubMed ID: 11205923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-mediated endocytosis of G250 tumor-associated antigen allows targeted gene transfer to human renal cell carcinoma in vitro.
    Dürrbach A; Angevin E; Poncet P; Rouleau M; Chavanel G; Chapel A; Thierry D; Gorter A; Hirsch R; Charpentier B; Senik A; Hirsch F
    Cancer Gene Ther; 1999; 6(6):564-71. PubMed ID: 10608353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
    Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
    Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.
    Sier CF; Gelderman KA; Prins FA; Gorter A
    Int J Cancer; 2004 May; 109(6):900-8. PubMed ID: 15027124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of markers for the selection of patients undergoing renal cell carcinoma-specific immunotherapy.
    Seliger B; Menig M; Lichtenfels R; Atkins D; Bukur J; Halder TM; Kersten M; Harder A; Ackermann A; Beck J; Muehlenweg B; Brenner W; Melchior S; Kellner R; Lottspeich F
    Proteomics; 2003 Jun; 3(6):979-90. PubMed ID: 12833523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes.
    Engels B; Noessner E; Frankenberger B; Blankenstein T; Schendel DJ; Uckert W
    Hum Gene Ther; 2005 Jul; 16(7):799-810. PubMed ID: 16000062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of adenovirus to human renal cell carcinoma cells.
    Jongmans W; van den Oudenalder K; Tiemessen DM; Molkenboer J; Willemsen R; Mulders PF; Oosterwijk E
    Urology; 2003 Sep; 62(3):559-65. PubMed ID: 12946777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
    Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
    Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections.
    Bismar TA; Bianco FJ; Zhang H; Li X; Sarkar FH; Sakr WA; Grignon DJ; Che M
    Pathology; 2003 Dec; 35(6):513-7. PubMed ID: 14660102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.